Isolation and Characterization of Stemness Properties of Cancer Stem Cells with CD44+ Surface Marker from A2780 Cancer Cell Line

Document Type : Original Article (s)

Authors

1 PhD Candidate of Molecular Genetics, Department of Biology, School of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

2 Associate Professor, Department of Biology, School of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran

3 Professor, Department of Medical Genetics, School of Science AND Medical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Ovarian cancer is the fifth leading cause of cancer death among women worldwide. Ovarian cancer is a heterogeneous disease that is genomically and histopathologically very diverse. In spite of usual treatments, recurrence of this cancer is very common due to the lack of complete eradication of certain types of cancer cells. These cells, known as cancer stem cells, have different stemness properties.Methods: In the present study, we isolated cancer stem cells (CSCs) with CD44 surface marker from ovarian A2780 cell line, and examined the invasion, growth, and differentiation properties and ALDH1 expression of isolated CD44+ cells compared to CD44- cells. The expression level of CD44 in this cell line was evaluated by flow cytometry (FCM) technique. Then, the isolation of these cells was performed by magnetic-activated cell sorting (MACS) technique using specific microbeads, and FCM was used to confirm the isolation efficacy. Invasion, growth rate, differentiation percentage, and expression rate of ALDH1 in CD44+ cells were evaluated and compared with CD44- cells.Findings: CD44+ CSCs, compared to CD44- cells, not only had the ability to invade other tissues, and differentiate to epithelial cells in culture medium containing serum, but also had faster growth rate and higher ALDH1expression in comparison with the control.Conclusion: Isolation of cancer stem cells has great importance in the targeted treatment of ovarian cancer and inhibition of tumor recurrence.

Keywords

References

  1. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353): 609-15.
  2. Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin 2018; 68(4): 284-96.
  3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Cancer incidence and mortality worldwide: IARC Cancer Base No. 10. Lyon, France: International Agency for Research on Cancer; 2010.
  4. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, et al. SEER Cancer Statistics Review, 1975-2008. Bethesda, MD: National Cancer Institute; 2011.
  5. Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 2003; 21(17): 3194-200.
  6. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1): 34-43.
  7. Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015; 386(9990): 249-57.
  8. Wright AA, Bohlke K, Armstrong DK, Bookman MA, Cliby WA, Coleman RL, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline. Gynecol Oncol 2016; 143(1): 3-15.
  9. Moghbeli M, Moghbeli F, Forghanifard MM, Abbaszadegan MR. Cancer stem cell detection and isolation. Med Oncol 2014; 31(9): 69.
  10. Moitra K. overcoming multidrug resistance in cancer stem cells. Biomed Res Int 2015; 2015: 635745.
  11. Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, et al. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. J Natl Cancer Inst 2014; 106(7): dju149.
  12. Wang QE. DNA damage responses in cancer stem cells: Implications for cancer therapeutic strategies. World J Biol Chem 2015; 6(3): 57-64.
  13. Shackleton M. Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol 2010; 20(2): 85-92.
  14. Rahman M, Jamil H, Akhtar N, Rahman K, Islam R, Asaduzzaman S. Stem cell and cancer stem cell: A tale of two cells. Progress in Stem Cell 2016; 3(2): 97-108.
  15. Thapa R, Wilson GD. The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. Stem Cells Int 2016; 2016: 2087204.
  16. Toole BP. Hyaluronan-CD44 interactions in cancer: paradoxes and possibilities. Clin Cancer Res 2009; 15(24): 7462-8.
  17. Ottevanger PB. Ovarian cancer stem cells more questions than answers. Semin Cancer Biol 2017; 44: 67-71.
  18. Hassan S, Muere A, Einstein G. Ovarian hormones and chronic pain: A comprehensive review. Pain 2014; 155(12): 2448-60.
  19. Naora H, Montell DJ. Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat Rev Cancer 2005; 5(5): 355-66.
  20. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010; 120(1): 41-50.
  21. Walters Haygood CL, Arend RC, Straughn JM, Buchsbaum DJ. Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival? World J Stem Cells 2014; 6(4): 441-7.
  22. Keyvani V, Farshchian M, Esmaeili SA, Yari H, Moghbeli M, Nezhad SRK, et al. Ovarian cancer stem cells and targeted therapy. J Ovarian Res 2019; 12(1): 120.
  23. Li SD, Howell SB. CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm 2010; 7(1): 280-90.
  24. Lee SJ, Ghosh SC, Han HD, Stone RL, Bottsford-Miller J, Shen DY, et al. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma. Clin Cancer Res 2012; 18(15): 4114-21.
  25. Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, et al. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. Gynecol Oncol 2013; 130(3): 579-87.
  26. Su D, Deng H, Zhao X, Zhang X, Chen L, Chen X, et al. Targeting CD24 for treatment of ovarian cancer by short hairpin RNA. Cytotherapy 2009; 11(5): 642-52.
  27. Chung H, Kim YH, Kwon M, Shin SJ, Kwon SH, Cha SD, et al. The effect of salinomycin on ovarian cancer stem-like cells. Obstet Gynecol Sci 2016; 59(4): 261-8.
  28. Zhang R, Zhang P, Wang H, Hou D, Li W, Xiao G, et al. Inhibitory effects of metformin at low concentration on epithelial-mesenchymal transition of CD44(+)CD117(+) ovarian cancer stem cells. Stem Cell Res Ther 2015; 6: 262.
  29. Miltenyi S, Muller W, Weichel W, Radbruch A. High gradient magnetic cell separation with MACS. Cytometry 1990; 11(2): 231-8.
  30. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-15.
  31. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 2007; 104(3): 973-8.
  32. Dalerba P, Dylla SJ, Park IK, Liu R, Wang X, Cho RW, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA 2007; 104(24): 10158-63.
  33. Reim F, Dombrowski Y, Ritter C, Buttmann M, Hausler S, Ossadnik M, et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res 2009; 69(20): 8058-66.
  34. Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett 2013; 338(1): 147-57.
  35. Garson K, Vanderhyden BC. Epithelial ovarian cancer stem cells: Underlying complexity of a simple paradigm. Reproduction 2015; 149(2): R59-R70.
  36. Shah V, Taratula O, Garbuzenko OB, Taratula OR, Rodriguez-Rodriguez L, Minko T. Targeted nanomedicine for suppression of CD44 and simultaneous cell death induction in ovarian cancer: an optimal delivery of siRNA and anticancer drug. Clin Cancer Res 2013; 19(22): 6193-204.
  37. Cao L, Shao M, Schilder J, Guise T, Mohammad KS, Matei D. Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer. Oncogene 2012; 31(20): 2521-34.
  38. Alvero AB, Chen R, Fu HH, Montagna M, Schwartz PE, Rutherford T, et al. Molecular phenotyping of human ovarian cancer stem cells unravels the mechanisms for repair and chemoresistance. Cell Cycle 2009; 8(1): 158-66.
  39. Alvero AB, Fu HH, Holmberg J, Visintin I, Mor L, Marquina CC, et al. Stem-like ovarian cancer cells can serve as tumor vascular progenitors. Stem Cells 2009; 27(10): 2405-13.
  40. Wei X, Dombkowski D, Meirelles K, Pieretti-Vanmarcke R, Szotek PP, Chang HL, et al. Mullerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proc Natl Acad Sci U S A 2010; 107(44): 18874-9.
  41. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, et al. CD44+/. Clin Exp Metastasis 2012; 29(8): 939-48.
  42. Mansouri A, Foroughmand AM, Abbaszadegan MR, Memar B, Mahmoudian RA, Gholamin M. Expression analysis of CD44 isoforms S and V3, in patients with esophageal squamous cell carcinoma. Iran J Basic Med Sci 2015; 18(4): 380-4.
  43. Moghbeli M, Mosannen MH, Memar B, Forghanifard MM, Gholamin M, Abbaszadegan MR. Role of MAML1 in targeted therapy against the esophageal cancer stem cells. J Transl Med 2019; 17(1): 126.
  44. Almanaa TN, Geusz ME, Jamasbi RJ. A new method for identifying stem-like cells in esophageal cancer cell lines. J Cancer 2013; 4(7): 536-48.
  45. Song J, Chang I, Chen Z, Kang M, Wang CY. Characterization of side populations in HNSCC: highly invasive, chemoresistant and abnormal Wnt signaling. PLoS One 2010; 5(7): e11456.
  46. Ruan Z, Liu J, Kuang Y. Isolation and characterization of side population cells from the human ovarian cancer cell line SK-OV-3. Exp Ther Med 2015; 10(6): 2071-8.

Files

History

  • Receive Date: 07 June 2021
  • Revise Date: 01 November 2024
  • Accept Date: 06 April 2022

Share

How to cite

Statistics